Galecto Starts Dosing In Mid-Stage Myelofibrosis Trial

by Vandana Singh, Benzinga Editor

August 18, 2021 9:25 AM | 1 min read |

Galecto Inc GLTO has announced the treatment of the first patient in a Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis.
Myelofibrosis, a form of chronic leukemia, is a rare type of blood cancer in which the normal bone marrow is destroyed by fibrous scar tissue that does not produce blood cells.
The open-label MYLOX-1 trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GB2064 in 16 patients over 9 months.
The trial will also assess the impact on fibrosis and quantification of the tissue targeting of GB2064 and other aspects of clinical response in myelofibrosis.
Price Action: GLTO shares are up 5.4% at $4.08 during the premarket session on the last check Wednesday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.